GH

Guardant Health, Inc.

Services-Medical Laboratories · SIC 8071CIK 1576280Held by 8 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$982.0M

Net Income FY2025

$(416.0M)

EPS (Basic, as reported)

$-3.32

Net Margin FY2025

-42.4%

ROE FY2025

419.2%

Total Equity

$(99.0M)

Shares Out

134M

Business description

Guardant Health, Inc. — Services-Medical Laboratories. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2016–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 25 → 982 +50.4% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue255091214287374450564739982

Cost of revenue———————(227)(290)(349)

Research & development(11)(26)(51)(86)(150)(263)(374)(367)(348)(364)

Selling & marketing(26)(32)(53)(78)(107)(192)(300)(295)(365)(495)

General & administrative(10)(37)(36)(61)(193)(207)(164)(156)(180)(211)

Total operating expenses(69)(126)(184)(297)(542)(785)(994)(1,129)(1,183)(1,419)

Operating income(44)(77)(93)(82)(255)(411)(544)(565)(444)(437)

Interest expense(3)(3)(1)(1)(5)(3)(3)(3)(3)(4)

Interest & investment income125141046355434

Other income (expense), net0(1)50425(13)53(43)(10)

Pre-tax income(46)(83)(84)(70)(246)(384)(653)(479)(435)(418)

Income tax expense000(2)00(1)(1)(1)(1)

Net income(46)(83)(85)(76)(246)(385)(655)(479)(436)(416)

EPS — basic———($0.84)($2.60)($4.00)($6.41)($4.28)($3.56)($3.32)

EPS — diluted———($0.84)($2.60)($4.00)($6.41)($4.28)($3.56)($3.32)

Shares outstanding — basic (M)———9198101102112123125

Shares outstanding — diluted (M)———9198101102112123125

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.